Edward Hurwitz

CIK 1211840 · last filed 2026-06-09

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$4.94M
Companies
6
Total Filings
50
Lifetime Open-Market Net
-$13.93M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MGNX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers
ALTA BIOPHARMA PARTNERS III LP — 16 joint filings, latest 2014-02-05
Farah Champsi — 16 joint filings, latest 2014-02-05
Edward Penhoet — 16 joint filings, latest 2014-02-05
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG — 12 joint filings, latest 2014-02-05
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC — 12 joint filings, latest 2014-02-05
Jean Deleage — 9 joint filings, latest 2010-10-27
Alix Marduel — 6 joint filings, latest 2008-09-05
Garrett Gruener — 4 joint filings, latest 2007-01-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DYN Director 91,081 $16.09 $1.47M $0 7 2026-06-09
MGNX Director 1,752,820 $1.99 $3.48M -$11.19M 18 2026-05-20
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Director 0 $0.39 $0 $0 12 2022-12-01
Tvardi Therapeutics, Inc. (CARA) Delisted Director 1,200 $15.96 $19.2K $1.24M 2 2014-02-05
Viracta Therapeutics, Inc. (SNSS) Delisted Director 826 $18.62 $15.4K -$4.49M 9 2013-07-02
Molecular Templates, Inc. (THLD) Delisted 139,693 — — $500.0K 1 2009-10-06

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
DYN MPM BioVentures 2018
See footnote
91,081 100.0% 2020-09-23
Total 91,081
MGNX Direct 47,824 2.7% 2026-05-20
See Footnote 1,704,996 97.3% 2014-02-18
Total 1,752,820
AGTC Direct 0 — 2022-12-01
By Hurwitz/Lichtenfeld Revocable Trust 0 — 2022-12-01
Total 0
CARA Alta BioPharma Partners III, L.P.
See Footnote
1,200 100.0% 2014-02-05
Total 1,200
SNSS See Footnote 826 100.0% 2010-07-02
Total 826
No longer reported
By Fund 0 — last 2009-12-16
THLD Direct 130,902 93.7% 2009-10-06
See footnotes 8,791 6.3% 2009-10-06
Total 139,693

Recent Filings · Page 5 of 5

50 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2012-07-02 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
2011-07-05 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
2010-07-02 Viracta Therapeutics, Inc. (SNSS) Delisted Mixed +16,909,694 $3.28M EDGAR
2010-06-08 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
2009-12-16 Viracta Therapeutics, Inc. (SNSS) Delisted Sell (S) −2,232,464 -$4.49M EDGAR
2009-11-03 Viracta Therapeutics, Inc. (SNSS) Delisted Buy (P) — $0 EDGAR
2009-10-06 Molecular Templates, Inc. (THLD) Delisted Buy (P) +261,780 $500.0K EDGAR
2009-09-08 — Sell (S) −717,837 -$161.5K
2009-06-19 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
2009-04-07 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
Showing 41–50 of 50
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).